Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with improved long-term graft survival and overall survival, according to study data
Beneficiaries may need to meet requirements related to: Age Body mass index, or BMI A prescription for weight loss or maintaining weight reduction Use of the medication along with lifestyle modifications Other qualifying health conditions CMS guidance indicates that the program is designed for beneficiaries seeking GLP-1 medications solely to reduce excess body weight or maintain weight reduction
The front desk is on top of things and their virtual interface is straightforward and easy to navigate
What you want to achieve Relevant medical info Your personalized stack This questionnaire is informational only and does not constitute medical advice
